ERBB2 and metabolic syndrome: Survival analyses were conducted for patients with different molecular subtypes, and MetS was associated with poorer DFS in patients with the HR+/HER+ subtype, but not in patients with HR+/HER–, HR–/HER2+, or HR–/HER2– subtype (Figure S1).